Prexton Therapeutics

Lundbeck to buy Prexton for phase 2 Parkinson’s drug

The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.

Nick Paul Taylor Mar 16, 2018 6:52am

EuroBiotech: More Articles of Note

Jul 13, 2017 6:15am

Serono spinout raises €29M for phase 2 Parkinson’s trials

Feb 7, 2017 5:05am

Serono spinout plots path forward for Parkinson’s drug

Sep 19, 2016 9:19am